Metraipolis › archive › dc_045b8e3ee596
Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models — Europe PMC PMID:41697749
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41697749
- DOI
- 10.1172/jci197192
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-05T18:04:44.039Z
- SHA-256 of the archived text
cb686987d2f302ae2114612a15c824d287352f8a194ca5728576cbe4aa9880b8- Stable URL of this page
https://metraipolis.com/documento/dc_045b8e3ee596
How to cite
Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models — Europe PMC PMID:41697749 — Europe PMC (en), https://europepmc.org/article/MED/41697749 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_045b8e3ee596 (Metraipolis archive dc_045b8e3ee596, sha256 cb686987d2f302ae2114612a15c824d287352f8a194ca5728576cbe4aa9880b8)
BibTeX
@misc{dc045b8e3ee596,
title = {Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models — Europe PMC PMID:41697749},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41697749},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_045b8e3ee596; sha256 cb686987d2f302ae2114612a15c824d287352f8a194ca5728576cbe4aa9880b8},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41697749. Agents can read the archived copy with the MCP tool read_document.